Pharmaceutical

SaneVax launches critical evaluation of Gardail vaccine, HPV virus

S.A.N.E. VAX, Inc., is newly established non-profit organization dedicated to promoting  safe, affordable, necessary and effective vaccines and vaccination practices through education and information. Its mission is two-fold: to provide information individuals need to make informed decisions prior to vaccination, and to help people locate appropriate medical and legal assistance if they or a loved one suffers from a serious adverse event after a vaccination. The organization is beginning its work with a critical evaluation of the drug Gardasil.

Manufactured by Merck & Co., Gardasil is promoted as a vaccination to protect young women against cervical cancer. What the drug actually does is guard against four out of about 40 types of human papillomavirus, or HPV. HPV is a sexually transmitted virus linked to the development of cervical cancer. Recently, recommended use of Gardasil has been expanded to include vaccinations for boys and young men, also for the prevention and spread of HPV.

However, since its introduction in 2006, Gardasil has been linked to a number of serious adverse events, including seizures and auto-immune disorders. More than 50 young women have died shortly after receiving the Gardasil vaccine.

In addition to these reports, SaneVax, Inc., is concerned about potential HPV vaccine-induced increased risks of cancer.There have been 283 cases of post-vaccination abnormal PAP smears reported to the Vaccine Adverse Event Reporting System (VAERS), with more reports of high-risk HPV, cervical lesions and cervical cancer also beginning to be recorded following vaccinations with Gardasil. Also, data collected by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) indicate exposure to HPV prior to vaccination with Gardasil raises a woman’s risk of cervical cancer by 44.6 percent.

SaneVax will operate a comprehensive website with news, research, videos, profiles of victims, a forum and more. It also plans to offer affordable, highly sensitive HPV testing using specific genotyping by DNA sequencing for pre- and post-vaccination.

“Pre- and post-HPV testing is crucial to identify whether a young woman has already been exposed to HPV, and to try and understand the mechanisms of action causing the injury and death of innocent girls after innoculation,” says SaneVax, Inc., board member Leslie Carol Botha, a Women’s Health educator and broadcast journalist.

Other board members include Norma Erickson (Chairman of the Board); Rosemary Mathis, who believes her daughter was injured by the Gardasil vaccine; Freda Birrell, political lobbyist int he UK and Scotland; and Janny Stokvis, vaccine researcher. They hope to expand the mission of SaneVax, Inc., to eventually include research, studies and data on all vaccines marketed in the United States.

For more information, visit sanevax.org or email info@sanevax.org.